We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+50.39%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$3.65B
AUM Growth
+$1.23B
Cap. Flow
+$333M
Cap. Flow %
9.14%
Top 10 Hldgs %
23.51%
Holding
147
New
14
Increased
82
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$36.8M
2
UNH icon
UnitedHealth
UNH
+$30.1M
3
RPRX icon
Royalty Pharma
RPRX
+$24.7M
4
NVAX icon
Novavax
NVAX
+$21.8M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$19.5M

Top Sells

Rank Stock Value
1
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$42.7M
2
ISRG icon
Intuitive Surgical
ISRG
+$17.5M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$6.7M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.68M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.96M

Sector Composition

Rank Sector Weight
1 Healthcare 96.99%
2 Miscellaneous 1.37%
3 Consumer Staples 1.09%
4 Consumer Discretionary 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
101
Prothena Corp
PRTA
$428M
$10.3M 0.28%
989,218
+489,218
+98% +$5.44M
ELVN icon
102
Enliven Therapeutics
ELVN
$3.91B
$10.1M 0.28%
91,183
-20,301
-18% -$2.27M
SWAV
103
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$9.36M 0.26%
+197,500
New +$8.14M
GMDA
104
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$9.22M 0.25%
2,016,656
+1,016,656
+102% +$4.67M
LEGN icon
105
Legend Biotech
LEGN
$3.44B
$8.76M 0.24%
+205,896
New +$8.04M
PRTK
106
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$8.64M 0.24%
1,655,164
+128,854
+8% +$572K
RPTX
107
DELISTED
Repare Therapeutics
RPTX
$8.53M 0.23%
+274,815
New +$8.82M
OBSV
108
DELISTED
ObsEva SA Ordinary Shares
OBSV
$8.38M 0.23%
1,423,552
+23,552
+2% +$88.9K
SPRO icon
109
Spero Therapeutics
SPRO
$65.8M
$8.32M 0.23%
615,177
+10,177
+2% +$114K
OSW icon
110
OneSpaWorld
OSW
$2.2B
$8.3M 0.23%
1,740,000
+690,000
+66% +$3.75M
STAA icon
111
STAAR Surgical
STAA
$1.13B
$8M 0.22%
130,000
-25,000
-16% -$1.02M
CHMA
112
DELISTED
Chiasma, Inc. Common Stock
CHMA
$7.49M 0.21%
1,392,312
+42,312
+3% +$233K
BLU
113
DELISTED
BELLUS Health Inc.
BLU
$7.16M 0.2%
+696,115
New +$7.06M
NGM
114
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$7.05M 0.19%
357,409
+6,309
+2% +$121K
IGMS
115
DELISTED
IGM Biosciences
IGMS
$6.96M 0.19%
+95,278
New +$5.79M
ANAB icon
116
AnaptysBio
ANAB
$1.62B
$6.85M 0.19%
306,713
+6,713
+2% +$123K
TXG icon
117
10x Genomics
TXG
$9.69B
$6.79M 0.19%
76,000
– –
XENT
118
DELISTED
Intersect ENT, Inc
XENT
$6.77M 0.19%
500,000
– –
MGNX icon
119
MacroGenics
MGNX
$257M
$6.55M 0.18%
234,516
+4,516
+2% +$78.4K
XENE icon
120
Xenon Pharmaceuticals
XENE
$5.45B
$6.47M 0.18%
515,711
+15,711
+3% +$200K
TRIL
121
DELISTED
Trillium Therapeutics Inc.
TRIL
$6.17M 0.17%
762,618
+12,618
+2% +$78.1K
AKRO
122
DELISTED
Akero Therapeutics
AKRO
$6.05M 0.17%
242,985
+17,985
+8% +$411K
PASG icon
123
Passage Bio
PASG
$15.3M
$5.56M 0.15%
10,172
-1,078
-10% -$485K
BNR
124
Burning Rock Biotech
BNR
$123M
$5.4M 0.15%
+20,000
New +$5.48M
QTTB icon
125
Q32 Bio
QTTB
$333M
$5.34M 0.15%
19,535
-4,076
-17% -$1.09M
2 3 4
5
6

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Rock Springs Capital Management held 147 positions worth $3.65B, up 51% from $2.42B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management deployed $333M of net new capital in Q2 2020, opening 14 new positions and adding to 82 existing holdings. Its largest new stake was Royalty Pharma: 500,000 shares worth $24.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Intuitive Surgical, an estimated $17.5M trimmed.

  • Rock Springs Capital Management's largest Q2 2020 buy was Royalty Pharma: 500,000 shares worth $24.3M.
  • Rock Springs Capital Management added most to Centene in Q2 2020, an estimated $36.8M increase.
  • Rock Springs Capital Management's biggest Q2 2020 reduction was Intuitive Surgical, cutting an estimated $17.5M.
  • Rock Springs Capital Management fully exited Forty Seven, Inc. Common Stock in Q2 2020, selling an estimated $42.7M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $3.65B portfolio in Q2 2020.
  • Rock Springs Capital Management opened 14 new positions and closed 4 in Q2 2020.
  • Rock Springs Capital Management's portfolio value rose 51% quarter-over-quarter to $3.65B.

Based on Rock Springs Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.